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For many decades, cancer registries have been a cornerstone in monitoring cancer 
occurrence in different populations. Cancer registries in the Nordic countries are charac-
terized by a high level of completeness and excellent data quality.1 Cancer diagnoses are 
often validated through several procedures, with documentation of clinical evidence for 
the diagnosis. Cancer registries have proven very useful in monitoring cancer incidence, 
contributing significantly to our understanding of its origin and development. Some 
registries also have been used to monitor cancer survival at the population level.1
Since the early 1990s there has been an increasing demand to measure the 
  performance of health care systems in treating a number of diseases, including can-
cer.2 “Outcomes” refers to the results of the health care delivery process.3 For cancer 
treatments, the main outcomes are: 1) clinical status, including survival; 2) functional 
status; and 3) consumer satisfaction. Five-year overall survival has long constituted 
the main clinical outcome in cancer research.2
The aim of any system designed to monitor the performance of a health care 
system is to help clinicians and health care administrators detect suboptimal clinical 
practices and to guide clinical decisions and policy, with the overall goal of achieving 
measurable improvements in health care.3 An effective monitoring system must fulfill 
the following requirements:4
1.  Data must be continuously updated.
2.  Data must be complete and of adequate quality.
3.  Data must be accessible on a regional level, and preferably also on a hospital 
level.
4.  Data must contain relevant clinical endpoints.
5.  Data must be collected continuously in clinical practice.
Cancer registries often are limited in these respects. One problem is lag time in data 
delivery (in some cases several years). Another is that information on treatment is restricted 
to that available at the time of diagnosis. As well, some registries do not provide linkage 
to mortality data. Finally, data collected by cancer registries are not routinely returned to 
clinical departments, limiting the feedback received by the specific health care delivery 
points. Many cancer registries thus provide only an incomplete view of the clinical course 
of cancers.
In this Supplement to Clinical Epidemiology,   current   survival data after cancer 
treatment in Denmark are reported on a regional level. The analyses were based on 
  administrative hospital registry data linked to a civil registry, both of which are available Clinical Epidemiology
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in many countries, but much underutilized for the purpose 
of performance monitoring. The papers show improvements 
in prognosis for some cancers and less convincing results 
for others. Of note, the analyses were conducted in close 
collaboration among clinicians, epidemiologists, and statisti-
cians. Only a limited portion of available data was used in 
the papers presented here.
Hospital registries provide relevant, current, continuous, 
and complete patient data, including type of admission (acute/
elective), type of surgery, baseline and acquired comorbidities,5 
and certain complications such as deep venous thrombosis.6 
A significant portion of these data are of high quality. Other data 
are underutilized, and their quality and completeness remain 
unknown (eg, information on nonsurgical treatments,   including 
chemotherapy and radiation therapy, and   complications such as 
infections). The quality of data on such variables must be ascer-
tained before they are used for health care quality monitoring. 
Another issue is that the ICD-10 (International Classification of 
Diseases, 10th Revision) coding often used in hospital registries 
lacks information on cancer stage. While this is a limitation 
for some analyses, earlier average stage diagnosis over time 
may itself indicate improved performance of the health care 
system, so adjustment of survival rates for changes in stage at 
diagnosis would actually mask improvements of some aspects 
of health care delivery.
A number of outcome measures found in hospital regis-
tries are very relevant for monitoring treatment quality. These 
include postoperative mortality,7 repeat operations, duration 
of hospitalization, admission to an intensive care unit,8 use 
of blood transfusions,9 surgical complications such as lung 
embolism, readmissions for infection, and later occurrence 
of metastases.10 Thus, in contrast with cancer registries, 
hospital registries have the potential to provide longitudinal 
data on the clinical course of cancer patients, including the 
occurrence of cancer-related late effects of treatment or the 
cancer itself.11
How can such data be used in clinical practice? A good 
starting point is to compare one’s own clinical practice with 
best practices in evidence-based medicine.12 Defined guide-
lines are available for a number of diseases. If a gap is identi-
fied, its extent and the underlying reasons must be determined, 
possibly through audit. Clinicians can then develop tools to 
close this gap and examine their success through new analy-
ses. The present papers result from such a feedback system, 
showing the feasibility of a multidisciplinary approach and 
the potential to identify shortcomings in performance that, 
if corrected, would improve the survival and quality of life 
of cancer patients.
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